Actualités et vidéos - GlobeNewsWire Europe

· Consolidated revenue was $653 million for the second quarter of 2019, up 8.5%, and up 7.2% on an organic constant currency (OCC) basis. · Net income was $150 million for the second quarter of 2019, down 2.0%. Adjusted EBITDA, a non-GAAP measure, was $304 million, up 5.7%, and up 5.2% on an OCC basis. · Diluted earnings per share (diluted EPS) were $0.90 for the second quarter of 2019; diluted adjusted earnings per share (adjusted EPS), a non-GAAP measure, were $1.10. · Net cash provided by...

NOVARTIS FINANCE S.A. / Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will be presented in September at the ESC...

KINGSPORT, Tenn., July 25, 2019 - Eastman Chemical Company (NYSE: EMN) announced its second-quarter 2019 financial results. (In millions, except per share amounts) 2Q19 2Q18 Sales revenue $2,363 $2,621 Earnings before interest and taxes ("EBIT") $371 $491 Adjusted EBIT* $389 $447 Earnings per diluted share $1.85 $2.39 Adjusted earnings per diluted share* $1.99 $2.22 Net cash provided by operating activities $422 $443 Free cash flow* $330 $342 * For non-core and unusual items (including related...

Financiële resultaten over het eerste halfjaar: Omzet van €108,5 miljoen Operationeel verlies van €97,6 miljoen Nettoverlies van €95,9 miljoen Kaspositie op 30 juni 2019 van €1.148 miljoen Verdere uitbouw van onze brede en diepe pijplijn: Positieve resultaten aangekondigd voor de FINCH 1 & 3 Fase 3-studies met filgotinib in reuma Rekrutering afgerond van de ROCCELLA Fase 2b-studie met GLPG1972 voor artrose, met samenwerkingspartner Servier Fase 2-studie GECKO gestart met MOR106 in...

First half-year financial results: Group revenues of €108.5 million Operating loss of €97.6 million Net loss of €95.9 million Cash and cash equivalents on 30 June 2019 of €1,148 million Further development of our broad and deep pipeline: Reported positive data with filgotinib in FINCH 1 and 3 Phase 3 trials in rheumatoid arthritis Completed recruitment of ROCCELLA Phase 2b trial with GLPG1972 in osteoarthritis, with Servier Initiated GECKO Phase 2 trial in atopic dermatitis with MOR106...

Publication of the H1 2019 financial report as of June 30 th , 2019 Paris, July 25 th , 2019 - JCDecaux SA (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announced today that the H1 2019 financial report as of June 30 th , 2019 was filed with the French Financial Markets Authority ( Autorité des Marchés Financiers - AMF ) and is available to the public. H1 2019 financial report can be accessed and downloaded from the Company's website www.jcdecaux.com under the...

Mise à disposition du Rapport financier semestriel au 30 juin 2019 Paris, le 25 juillet 2019 - JCDecaux SA (Euronext Paris : DEC), numéro un mondial de la communication extérieure, annonce ce jour avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers son rapport financier semestriel au 30 juin 2019. Le rapport financier semestriel peut être consulté et téléchargé sur le site internet de la société à l'adresse www.jcdecaux.com , dans la...

Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of non-normal distribution (outliers) in 400mg OD In advanced patients, setanaxib 400mg BID achieved significant reductions in GGT (-32%) and ALP (-24%) Cash and cash equivalents of €4.5 million as of June 30, 2019, providing cash runway to April 2020 ARCHAMPS, France, July 25, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX...

H1 2019 results Adjusted revenue up +12.1% to €1,842.3 million Adjusted organic revenue up +5.2%, with Q2 at +5.1% Adjusted operating margin of €306.4 million, up +29.4% Adjusted EBIT, before impairment charge, of €136.1 million, up +58.6% Net income Group share of €96.0 million, up +86.8% Adjusted free cash flow of -€7.8 million, down -120.3% Adjusted organic revenue expected to be flat in Q3 2019 compared to Q3 2018 Paris, July 25 th , 2019 - JCDecaux SA (Euronext Paris: DEC), the...

Le setanaxib (GKT831) atteint la signification statistique (p=0,02) pour le critère d'efficacité principal à 400mg BID contre placébo, après correction des aberrations de distribution à 400mg OD Chez les patients à un stade avancé, le setanaxib à 400mg BID obtient des réductions significatives de la GGT (-32 %) et de la PAL (-24 %) Trésorerie et équivalents de trésorerie de 4,5 M€ au 30 juin 2019 offrant une visibilité financière jusqu'en avril 2020 ARCHAMPS, France, 25 juill....

Résultats du premier semestre 2019 Chiffre d'affaires ajusté en hausse de +12,1 % à 1 842,3 millions d'euros Croissance du chiffre d'affaires organique ajusté en hausse de +5,2 %, avec un 2 ème trimestre en hausse de +5,1 % Marge opérationnelle ajustée de 306,4 millions d'euros, en hausse de +29,4 % Résultat d'exploitation ajusté, avant charges de dépréciation, de 136,1 millions d'euros, en hausse de +58,6 % Résultat net part du Groupe de 96,0 millions d'euros, en hausse de +86,8 %...

Verisk and PASCO to Explore Strategic Alliance to Codevelop Solutions for Asian Markets JERSEY CITY, N.J., July 24, 2019 - Verisk (Nasdaq:VRSK), a leading data analytics provider, has signed a definitive agreement to acquire Keystone Aerial Surveys, Inc., to expand its aerial survey services. Keystone is the aerial survey business in the United States of PASCO CORPORATION (TSE:9232), Japan's largest geospatial service provider. Headquartered in Philadelphia, Pennsylvania, with branches in...

ARCHAMPS, France, July 24, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX ) a biopharmaceutical company and the leader in NOX therapies, will hold a conference call on July 25, 2019 at 2pm CEST, following publication of the second quarter financial results. The call will be hosted by Elias Papatheodorou, CEO of Genkyotex, Philippe Wiesel, Chief Medical Officer of Genkyotex and Alexandre Grassin, VP Finance & Administration. Participants numbers for the call:...

THOMASVILLE, GA; July 24, 2019-Flowers Foods (NYSE: FLO) will hold a live webcast on Thursday, August 8, 2019 to review second quarter earnings. The company expects the call to last approximately 60 minutes. The company will release earnings on Wednesday, August 7, 2019 after the market closes. What: Flowers Foods Second Quarter 2019 Earnings Conference Call Webcast When: Thursday, August 8, 2019 at 8:30 a.m. Eastern Where: www.flowersfoods.com/investors (Quarterly Updates) How: Live over the...

Zaandam, the Netherlands, July 23, 2019 - Ahold Delhaize has repurchased 541,000 of Ahold Delhaize common shares in the period from July 15, 2019 up to and including July 19, 2019. The shares were repurchased at an average price of €20.45 per share for a total consideration of €11.1 million. These repurchases were made as part of the €1 billion share buyback program announced on November 13, 2018. The total number of shares repurchased under this program to date is 31,483,687 common shares...

GREENWICH, Conn. - July 23, 2019 - XPO Logistics, Inc. (NYSE: XPO), a leading global provider of supply chain solutions, has been named a Top 100 Third-Party Logistics (3PL) Provider by Inbound Logistics magazine. This is XPO's sixth consecutive year on the list. In June, Inbound Logistics selected XPO as a Green 75 Supply Chain Partner for showing a strong commitment to environmentally friendly practices. Troy Cooper, president of XPO Logistics, said, "We're delighted to again receive this...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: OCTOPUS INVESTMENTS LIMITED (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: OCTOPUS INVESTMENTS LIMITED (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of...

SpareBank 1 SMN, SpareBank 1 Nord-Norge and Sparebank 1 Østlandet are presenting 2nd quarter 2019 financial results. Time: Thursday 8 August at 4.00 p.m. CET Place: Grand Hotel, Karl Johans gate 31, Oslo The presentations will be held by: Sparebank 1 Østlandet CEO Richard Heiberg and CFO Geir-Egil Bolstad SpareBank 1 Nord-Norge Group CEO Petter Høiseth and CFO Bengt Olsen SpareBank 1 SMN Group CEO Jan- Frode Janson and CFO Kjell Fordal The presentations will also be available by webcast:...

World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem "naxib" recognizes NOX inhibitors as a new therapeutic class The NOX inhibitor therapeutic class has significant potential in fibrotic, inflammatory, neurodegenerative, and oncology disorders ARCHAMPS, France, July 22, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX ) a biopharmaceutical company and the leader in NOX therapies,...